The precision medicine in oncology condition center is a comprehensive resource for clinical news on precision medicine in oncology. Read more at OncLive.
July 21st 2025
Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.
July 7th 2025
The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.
July 6th 2025
The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.
July 4th 2025
Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.
July 2nd 2025
Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.
July 1st 2025
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
June 30th 2025
China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.
June 29th 2025
Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
June 28th 2025
The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.
June 23rd 2025
The FDA approved Dato-DXd for previously treated, locally advanced or metastatic, EGFR-mutated non–small cell lung cancer.
June 19th 2025
Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.
June 15th 2025
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
June 14th 2025
The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.
June 13th 2025
TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.
June 11th 2025
The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.
June 7th 2025
Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.
June 2nd 2025
The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
May 31st 2025
MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.
Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.
May 30th 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.